Abalone Bio

Abalone Bio is dedicated to developing innovative antibody therapies for diseases with previously undruggable targets, impacting millions of lives. Their initial focus is on creating cell-specific antibody drugs to combat obesity and metabolic diseases, aiming to eliminate the gastrointestinal side effects that lead to a significant percentage of patients discontinuing GLP-1 drugs. Abalone Bio employs a unique high-throughput experimental measurement system that leverages artificial intelligence and machine learning. They have engineered cells to assess antibodies based on their pharmacological activity, rather than just structure or binding affinity, enabling the simultaneous evaluation of 100 million antibodies, exceeding the throughput of conventional methods by over 100 times. This proprietary activity dataset allows for the discovery of rare and optimized hits for challenging targets, particularly G-protein coupled receptors (GPCRs). Abalone Bio has a proven track record, having successfully developed antibody agonists for two out of the eight GPCRs ever targeted by biotech companies. They have also secured three partnerships, generating $3 million in revenue and $125 million in downstream value, and have received $7 million in non-dilutive grant funding for platform and program development, further validating their scientific approach.